Kadmon (KDMN) Getting Somewhat Positive Press Coverage, Report Shows

News coverage about Kadmon (NYSE:KDMN) has trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kadmon earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.5812130350058 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

A number of research firms recently issued reports on KDMN. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a report on Friday. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Kadmon in a report on Friday, December 15th. Finally, WBB Securities lowered Kadmon from a “hold” rating to a “sell” rating and set a $3.00 price target on the stock. in a report on Monday, October 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.65.

Shares of Kadmon (NYSE KDMN) traded up $0.36 on Friday, reaching $4.23. The company’s stock had a trading volume of 6,261,199 shares, compared to its average volume of 540,918. Kadmon has a 12 month low of $2.05 and a 12 month high of $5.07. The stock has a market cap of $304.35, a price-to-earnings ratio of -2.42 and a beta of 2.54.

Kadmon (NYSE:KDMN) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.04). The business had revenue of $2.28 million during the quarter, compared to the consensus estimate of $5.69 million. During the same quarter in the previous year, the company earned ($4.24) earnings per share. The company’s quarterly revenue was down 60.0% compared to the same quarter last year. equities research analysts anticipate that Kadmon will post -1.61 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.thestockobserver.com/2018/01/13/kadmon-kdmn-getting-somewhat-positive-press-coverage-report-shows.html.

Kadmon Company Profile

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Insider Buying and Selling by Quarter for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply